# NIH Reporter #2R01FD007632-05

ACCELERATE: An Efficient and Innovative Natural History Study Addressing Unmet Needs in Castleman Disease

**Recipient:** University of Pennsylvania

**Award Amount:** $600,000.00
**Ceiling:** $600,000.00

**Awarded:** September 21, 2026

**Identifier:** 2R01FD007632-05

FDA funding supports continued development of the ACCELERATE Castleman disease registry and research to improve diagnosis, identify clinically meaningful subgroups and treatment-response biomarkers, and evaluate repurposed medications.

### Description

Renewal of the FDA award supporting the ACCELERATE international, prospective natural history study of Castleman disease. The project will grow the patient registry, use machine learning and multi-omic and spatial-imaging data to improve diagnosis and identify patient subtypes and treatment-response predictors, and study real-world use of sirolimus and ruxolitinib.

[View original record](https://reporter.nih.gov/search/7U_RDKopbE--cH-2OrGcnA/project-details/11495236)